Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions

Cancer
Bassem I RazzoukSima Jeha

Abstract

The prognostic significance of age among pediatric patients with acute myeloid leukemia (AML) was investigated. The authors reviewed the outcome of 424 patients who were <or=21 years of age at the time of diagnosis of AML (excluding acute promyelocytic leukemia) between 1983 and 2002 at St. Jude Children's Research Hospital (n=288) or the M. D. Anderson Cancer Center (n=136). Two treatment eras (1983-1989 and 1990-2002) were examined because of the greater intensity of treatment during the recent era. After controlling for the effects of cytogenetics, white blood cell (WBC) count, French-American-British (FAB) subtype, and treatment era, they observed that age and treatment era interacted significantly in relation to event-free survival (EFS) (P=.033). Patients 10 years of age or older were at greater risk of an adverse event than younger patients in the recent era (hazard ratio=1.8; 95% confidence interval [CI]: 1.3-2.6; P=.005) but not in the early era. The rate of adverse events (death or recurrence) increased significantly with each year of age in the recent era (4.3%/year; 95% CI: 1.9-6.8%; P=.001) but not in the early era. The rate of death increased significantly with each year of age in both eras (4.4%/year; 95% CI: 2.3...Continue Reading

References

Mar 1, 1988·Clinical Pharmacology and Therapeutics·M PeetersA Zipursky
Jul 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D KalwinskyG V Dahl
Sep 1, 1986·Cancer·C K TebbiJ Mallon
Apr 1, 1980·The Journal of Allergy and Clinical Immunology·S R Hirsch, J H Kalbfleisch
Mar 1, 1995·Cancer Treatment Reviews·H A Davies, J S Lilleyman
Aug 27, 1998·The New England Journal of Medicine·C H Pui, W E Evans
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A KranceR C Ribeiro
Jan 16, 2002·Current Opinion in Oncology·Mikkael A Sekeres, Richard M Stone
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria E Suarez-AlmazorEduardo Bruera
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristine R CrewsRaul C Ribeiro
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles A Schiffer
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolas BoisselAndré Baruchel
Feb 21, 2004·Blood·Mikkael A SekeresUNKNOWN Cancer and Leukemia Group B
Apr 28, 2004·Seminars in Oncology·Marshall A Lichtman, Jacob M Rowe
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kamar GodderMary M Horowitz

❮ Previous
Next ❯

Citations

May 29, 2008·Current Treatment Options in Oncology·Jeffrey E Rubnitz
Jun 13, 2013·Current Oncology Reports·M Monica Gramatges, Karen R Rabin
Mar 15, 2011·Blood·William A Wood, Stephanie J Lee
Dec 25, 2013·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Shannon L MaudeRichard Aplenc
Oct 14, 2014·Journal of Cancer Epidemiology·Md Jobayer HossainSuzanne M McCahan
Mar 24, 2010·Pediatric Clinics of North America·Alan S WayneR Maarten Egeler
Feb 2, 2010·Hematology/oncology Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Feb 5, 2008·Pediatric Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Jul 1, 2009·European Journal of Haematology·Kalliopi N Manola
Sep 1, 2007·Pediatric Blood & Cancer·Jessica R RobersonBassem I Razzouk
Jun 8, 2012·Cancer·Jeffrey E RubnitzHiroto Inaba
Sep 7, 2013·British Journal of Haematology·Andrew E PlaceStephen E Sallan
Jul 27, 2015·Seminars in Oncology Nursing·Andrew J BukowinskiMaureen M O'Brien
Sep 7, 2011·Bone·Melanie M HagleitnerD Maroeska W M te Loo
Nov 12, 2016·Clinical Lymphoma, Myeloma & Leukemia·Syed Sameer NasirMike G Martin
Nov 20, 2016·American Journal of Hematology·Lena E WinestoneRichard Aplenc
Dec 30, 2017·Pediatric Blood & Cancer·Liezl Du PlessisCherry Mammen
Dec 17, 2021·International Journal of Cancer. Journal International Du Cancer·Maya SchulpenHenrike E Karim-Kos

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.